|
|
| Line 1: |
Line 1: |
|
| |
|
| ==Crystal structure of human TLR8 in complex with DS-877== | | ==Crystal structure of human TLR8 in complex with DS-877== |
| <StructureSection load='3wn4' size='340' side='right'caption='[[3wn4]], [[Resolution|resolution]] 1.81Å' scene=''> | | <StructureSection load='3wn4' size='340' side='right'caption='[[3wn4]]' scene=''> |
| == Structural highlights == | | == Structural highlights == |
| <table><tr><td colspan='2'>[[3wn4]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3WN4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3WN4 FirstGlance]. <br> | | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3WN4 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3WN4 FirstGlance]. <br> |
| </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=D87:2-BUTYLFURO[2,3-C]QUINOLIN-4-AMINE'>D87</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene></td></tr> | | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3wn4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3wn4 OCA], [https://pdbe.org/3wn4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3wn4 RCSB], [https://www.ebi.ac.uk/pdbsum/3wn4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3wn4 ProSAT]</span></td></tr> |
| <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3wn4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3wn4 OCA], [https://pdbe.org/3wn4 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3wn4 RCSB], [https://www.ebi.ac.uk/pdbsum/3wn4 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3wn4 ProSAT]</span></td></tr> | |
| </table> | | </table> |
| == Function ==
| |
| [[https://www.uniprot.org/uniprot/TLR8_HUMAN TLR8_HUMAN]] Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.<ref>PMID:17932028</ref>
| |
| <div style="background-color:#fffaf0;">
| |
| == Publication Abstract from PubMed ==
| |
| Toll-like receptor (TLR)-8 agonists activate adaptive immune responses by inducing robust production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds might be promising candidate vaccine adjuvants. Recently, a C2-butyl furo[2,3-c]quinoline was reported with purely TLR8 agonistic activity. This compound was successfully co-crystallized with the human TLR8 ectodomain, and the co-crystal structure revealed ligand-induced reorganization of the binding pocket of TLR8. The loss of a key hydrogen bond between the oxygen atom of the furanyl ring of the agonist and Thr 574 in TLR8 suggested that the furan ring is dispensable. Employing a disconnection strategy, 3- and 4-substituted aminoquinolines were investigated. Focused structure-based ligand design studies led to the identification of 3-pentyl-quinoline-2-amine as a novel, structurally simple, and highly potent human TLR8-specific agonist (EC50 =0.2 muM). Preliminary evaluation of this compound in ex vivo human blood assay systems revealed that it retains prominent cytokine-inducing activity. Together, these results indicate the suitability of this compound as a novel vaccine adjuvant, warranting further investigation.
| |
|
| |
| Structure-Based Design of Novel Human Toll-like Receptor 8 Agonists.,Kokatla HP, Sil D, Tanji H, Ohto U, Malladi SS, Fox LM, Shimizu T, David SA ChemMedChem. 2014 Jan 28. doi: 10.1002/cmdc.201300573. PMID:24474703<ref>PMID:24474703</ref>
| |
|
| |
| From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
| |
| </div>
| |
| <div class="pdbe-citations 3wn4" style="background-color:#fffaf0;"></div>
| |
|
| |
|
| ==See Also== | | ==See Also== |
| *[[Toll-like Receptor 3D structures|Toll-like Receptor 3D structures]] | | *[[Toll-like Receptor 3D structures|Toll-like Receptor 3D structures]] |
| == References ==
| |
| <references/>
| |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
| [[Category: Ohto, U]] | | [[Category: Ohto U]] |
| [[Category: Shimizu, T]] | | [[Category: Shimizu T]] |
| [[Category: Tanji, H]] | | [[Category: Tanji H]] |
| [[Category: Antiviral-antitumor drug binding]]
| |
| [[Category: Glycosylation]]
| |
| [[Category: Immune system]]
| |
| [[Category: Innate immunity]]
| |
| [[Category: Leucine rich repeat]]
| |
| [[Category: Rna]]
| |
| [[Category: Rna recognition]]
| |
| [[Category: Ssrnar]]
| |
| [[Category: Structure-based ligand design]]
| |
| [[Category: Tlr8-specific agonist]]
| |
| [[Category: Vaccine adjuvant]]
| |